The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86

Papers of special note have been highlighted as: ▪ of interest

Bibliography

• 1  Holland JP, Williamson MJ, Lewis JS. Unconventional nuclides for radiopharmaceuticals. Mol. Imaging9(1),1–20 (2010).
  Medline CASGoogle Scholar
• 2  Meijs WE, Herscheid JDM, Haisma HJ, Wijbrandts F, van Langevelde F, van Leuffen PJ. Production of highly pure no-carrier added ⁸⁹Zr for the labeling of antibodies and a positron emitter. Appl. Radiat. Isot.45,1143–1147 (1994).▪ Provides details of zirconium-89 production.
  CASGoogle Scholar
• 3  Dejesus OT, Nickles RJ. Production and purification of Zr-89, a potential pet antibody label. Appl. Radiat. Isot.41(8),789–790 (1990).
  CASGoogle Scholar
• 4  Avila-Rodriguez MA, Nye JA, Nickles RJ. Production and separation of noncarrier-added ⁸⁶Y from enriched 86Sr targets. Appl. Radiat. Isot.66(1),9–13 (2008).
  Medline CASGoogle Scholar
• 5  Reischl G, Rosch F, Machulla HJ. Electrochemical separation and purification of yttrium-86. Radiochimica Acta90(4),225–228 (2002).
  CASGoogle Scholar
• 6  Sun X, Anderson CJ. Production and applications of copper-64 radiopharmaceuticals. Methods Enzymol.386,237–261 (2004).
  Medline CASGoogle Scholar
• 7  McCarthy DW, Shefer RE, Klinkowstein RE et al. Efficient production of high specific activity ⁶⁴Cu using a biomedical cyclotron. Nucl. Med. Biol.24(1),35–43 (1997).▪ Provides details of copper-64 production.
  Medline CASGoogle Scholar
• 8  Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem. Rev.110(5),2858–2902 (2010).▪ Provides details on chelators for radiometals.
  Medline CASGoogle Scholar
• 9  Pal S, Chattopadhyay S, Das MK, Sudersanan M. Production and separation of no-carrier-added radioactive tracers of yttrium, strontium and rubidium from heavy-ion irradiated germanium target: applicability to the standardization of a separation technique for production of positron-emitting radionuclide Y-86. Appl. Radiat. Isot.64(12),1521–1527 (2006).
  Medline CASGoogle Scholar
• 10  Yoo J, Tang L, Perkins TA et al. Preparation of high specific activity Y-86 using a small biomedical cyclotron. Nucl. Med. Biol.32(8),891–897 (2005).
  Medline CASGoogle Scholar
• 11  Zweit J, Downey S, Sharma HL. Production of no-carrier-added zirconium-89 for positron emission tomography. Appl. Radiat. Isot.42(2),199–201 (1991).
  CASGoogle Scholar
• 12  Hohn A, Zimmermann K, Schaub E, Hirzel W, Schubiger PA, Schibli R. Production and separation of ‘‘nonstandard’’ PET nuclides at a large cyclotron facility: the experiences at the Paul Scherrer Institute in Switzerland. Q. J. Nucl. Med. Mol. Imaging52(2),145–150 (2008).
  Medline CASGoogle Scholar
• 13  Link JM, Krohn KA, Eary JF. ⁸⁹Zr for antibody labeling and positron tomography. J. Labeled Compd Radiopharm.23,1296–1297 (1986).
  Google Scholar
• 14  Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. ⁸⁹Zr immuno-PET: comprehensive procedures for the production of ⁸⁹Zr-labeled monoclonal antibodies. J. Nucl. Med.44(8),1271–1281 (2003).▪ Overview of zirconium-89 antibody labeling.
  Medline CASGoogle Scholar
• 15  Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr. Pharm. Des.13(1),3–16 (2007).
  Medline CASGoogle Scholar
• 16  Zinn KR, Chaudhuri TR, Cheng TP, Morris JS, Meyer WA, Jr. Production of no-carrier-added ⁶⁴Cu from zinc metal irradiated under boron shielding. Cancer73(Suppl. 3),774–778 (1994).
  Medline CASGoogle Scholar
• 17  Szelecsenyi F, Blessing G, Qaim SM. Excitation function of proton induced nuclear reactions on enriched ⁶¹Ni and ⁶⁴Ni: possibility of production of no-carrier-added ⁶¹Cu and ⁶⁴Cu at a small cyclotron. Appl. Radiat. Isot.44,575–580 (1993).
  CASGoogle Scholar
• 18  Smith SV, Waters D, DiBartolo N. Carrier-free copper-64 isolated from Ga-67 waste for use in PET and therapy. J. Nucl. Med.37(5),894–894 (1996).
  Google Scholar
• 19  Qaim SM, Bisinger T, Hilgers K, Nayak D, Coenen HH. Positron emission intensities in decay of ⁶⁴Cu, ⁷⁶Br, and ¹²⁴I. Radiochimica Acta95,67–73 (2007).
  CASGoogle Scholar
• 20  Firestone RB, Baglin CM, Chu SYF. In: Table of Isotopes, Volumes 1–2. Shirley VS (Ed.). John Wiley & Sons, Inc., NY, USA (1996).
  Google Scholar
• 21  Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol.36(7),729–739 (2009).
  Medline CASGoogle Scholar
• 22  Kandil SA, Scholten B, Saleh AM, Youssef SM, Qaim SM, Coenen HH. A comparative study on the separation of radiozirconium via ion-exchange and solvent extraction techniques, with particular reference to the production of ⁸⁸Zr and ⁸⁹Zr in proton induced reactions on yttrium. J. Radioanal. Nucl. Chem.274,45–52 (2007).
  CASGoogle Scholar
• 23  Nayak TK, Brechbiel MW. Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug. Chem.20(5),825–841 (2009).▪ Summary of immuno-PET.
  Medline CASGoogle Scholar
• 24  Perk LR, Visser OJ, Stigter-van Walsum M et al. Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography. Eur. J. Nucl. Med. Mol. Imaging33(11),1337–1345 (2006).
  Medline CASGoogle Scholar
• 25  Welch MJ, Laforest R, Lewis JS. Production of nonstandard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides. Ernst Schering Res. Found. Workshop (62), 159–181 (2007).
  MedlineGoogle Scholar
• 26  Moi MK, Meares CF, McCall MJ, Cole WC, DeNardo SJ. Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent. Anal. Biochem.148(1),249–253 (1985).
  Medline CASGoogle Scholar
• 27  Shokeen M, Anderson CJ. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc. Chem. Res.42(7),832–841 (2009).
  Medline CASGoogle Scholar
• 28  Hoffman TJ, Smith CJ. True radiotracers: Cu-64 targeting vectors based upon bombesin peptide. Nucl. Med. Biol.36(6),579–585 (2009).
  Medline CASGoogle Scholar
• 29  Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother. Radiopharm.24(4),379–393 (2009).
  Medline CASGoogle Scholar
• 30  Tatum JL, Kelloff GJ, Gillies RJ et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int. J. Radiat. Biol.82(10),699–757 (2006).
  Medline CASGoogle Scholar
• 31  Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of ⁶⁴Cu-ATSM and ⁶⁰Cu-ATSM in cancer of the uterine cervix. J. Nucl. Med.49(7),1177–1182 (2008).
  MedlineGoogle Scholar
• 32  Dehdashti F, Mintun MA, Lewis JS et al.In vivo assessment of tumor hypoxia in lung cancer with ⁶⁰Cu-ATSM. Eur. J. Nucl. Med. Mol. Imaging30(6),844–850 (2003).
  Medline CASGoogle Scholar
• 33  Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with ⁶⁰Cu-ATSM: relationship to therapeutic response – a preliminary report. Int. J. Radiat. Oncol. Biol. Phys.55(5),1233–1238 (2003).
  MedlineGoogle Scholar
• 34  Lewis JS, Connett JM, Garbow JR et al. Copper-64-pyruvaldehyde-bis(N(4)-methylthiosemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy response with microPET and magnetic resonance imaging. Cancer Res.62(2),445–449 (2002).
  Medline CASGoogle Scholar
• 35  Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J. Nucl. Med.49(Suppl. 2),129S–148S (2008).
  Medline CASGoogle Scholar
• 36  Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. (43), 4893–4902 (2007).
  MedlineGoogle Scholar
• 37  Lapi SE, Voller TF, Welch MJ. Positron emission tomography imaging of hypoxia. PET Clin.4(1),39–47 (2009).
  MedlineGoogle Scholar
• 38  Lewis J, Laforest R, Buettner T et al. Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): an agent for radiotherapy. Proc. Natl Acad. Sci. USA98(3),1206–1211 (2001).
  Medline CASGoogle Scholar
• 39  Fodero-Tavoletti MT, Villemagne VL, Paterson BM et al. Bis(thiosemicarbazonato) Cu-64 complexes for positron emission tomography imaging of Alzheimer’s disease. J. Alzheimers Dis.20(1),49–55 (2010).
  Medline CASGoogle Scholar
• 40  Lim S, Paterson BM, Fodero-Tavoletti MT et al. A copper radiopharmaceutical for diagnostic imaging of Alzheimer’s disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-β plaques. Chem. Commun. (Camb.)46(30),5437–5439 (2010).
  Medline CASGoogle Scholar
• 41  Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J. Nucl. Med.36(10),1825–1835 (1995).
  Medline CASGoogle Scholar
• 42  Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr. Rev.12(4),450–482 (1991).
  Medline CASGoogle Scholar
• 43  Anderson CJ, Pajeau TS, Edwards WB, Sherman EL, Rogers BE, Welch MJ. In vitro and in vivo evaluation of copper-64-octreotide conjugates.J. Nucl. Med.36(12),2315–2325 (1995).
  Medline CASGoogle Scholar
• 44  Dehdashti F, Anderson CJ, Trask DD et al. Initial results with PET imaging using Cu-64-labeled TETA-octreotide in patients with carinoid tumor. J. Nucl. Med.38,103P (1997).
  MedlineGoogle Scholar
• 45  Lewis JS, Lewis MR, Srinivasan A, Schmidt MA, Wang J, Anderson CJ. Comparison of four ⁶⁴Cu-labeled somatostatin analogs in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. J. Med. Chem.42(8),1341–1347 (1999).
  Medline CASGoogle Scholar
• 46  Clifford T, Boswell CA, Biddlecombe GB, Lewis JS, Brechbiel MW. Validation of a novel CHX-A’’ derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A’’-octreotide. J. Med. Chem.49(14),4297–4304 (2006).
  Medline CASGoogle Scholar
• 47  Gugger M, Reubi JC. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. Am. J. Pathol.155(6),2067–2076 (1999).
  Medline CASGoogle Scholar
• 48  Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res.59(5),1152–1159 (1999).
  Medline CASGoogle Scholar
• 49  Scheffel U, Pomper MG. PET imaging of GRP receptor expression in prostate cancer. J. Nucl. Med.45(8),1277–1278 (2004).
  Medline CASGoogle Scholar
• 50  Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), β-ALA(11), PHE(13), NLE(14)] bombesin(6–14). Clin. Cancer Res.8(4),1139–1146 (2002).
  Medline CASGoogle Scholar
• 51  Parry JJ, Andrews R, Rogers BE. MicroPET imaging of breast cancer using radiolabeled bombesin analogs targeting the gastrin-releasing peptide receptor. Breast Cancer Res. Treat.101(2),175–183 (2007).
  Medline CASGoogle Scholar
• 52  Rogers BE, Bigott HM, McCarthy DW et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a ⁶⁴Cu-labeled bombesin analog. Bioconjug. Chem.14(4),756–763 (2003).
  Medline CASGoogle Scholar
• 53  Parry JJ, Kelly TS, Andrews R, Rogers BE. In vitro and in vivo evaluation of ⁶⁴Cu-labeled DOTA-linker-bombesin(7–14) analogs containing different amino acid linker moieties. Bioconjug. Chem.18(4),1110–1117 (2007).
  Medline CASGoogle Scholar
• 54  Yang YS, Zhang X, Xiong Z, Chen X. Comparative in vitro and in vivo evaluation of two ⁶⁴Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl. Med. Biol.33(3),371–380 (2006).
  Medline CASGoogle Scholar
• 55  Chen X, Park R, Hou Y et al. MicroPET and autoradiographic imaging of GRP receptor expression with ⁶⁴Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J. Nucl. Med.45(8),1390–1397 (2004).
  Medline CASGoogle Scholar
• 56  Prasanphanich AF, Nanda PK, Rold TL et al. [⁶⁴Cu-NOTA-8-Aoc-BBN(7–14)NH₂] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc. Natl Acad. Sci. USA104(30),12462–12467 (2007).
  Medline CASGoogle Scholar
• 57  Garrison JC, Rold TL, Sieckman GL et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using ⁶⁴Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J. Nucl. Med.48(8),1327–1337 (2007).
  Medline CASGoogle Scholar
• 58  Hwang R, Varner J. The role of integrins in tumor angiogenesis. Hematol. Oncol. Clin. North Am.18(5),991–1006 (2004).
  MedlineGoogle Scholar
• 59  Tucker GC. αv integrin inhibitors and cancer therapy. Curr. Opin. Investig. Drugs4(6),722–731 (2003).
  Medline CASGoogle Scholar
• 60  Sprague JE, Kitaura H, Zou W et al. Noninvasive imaging of osteoclasts in parathyroid hormone-induced osteolysis using a ⁶⁴Cu-labeled RGD peptide. J. Nucl. Med.48(2),311–318 (2007).
  Medline CASGoogle Scholar
• 61  Varner JA, Cheresh DA. Tumor angiogenesis and the role of vascular cell integrin αvβ3. Important Adv. Oncol.69–87 (1996).
  MedlineGoogle Scholar
• 62  Ruoslahti E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol.12,697–715 (1996).
  Medline CASGoogle Scholar
• 63  Wei L, Ye Y, Wadas TJ et al. (64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. Nucl. Med. Biol.36(3),277–285 (2009).
  Medline CASGoogle Scholar
• 64  Chen X, Liu S, Hou Y et al. MicroPET imaging of breast cancer αv-integrin expression with ⁶⁴Cu-labeled dimeric RGD peptides. Mol. Imaging Biol.6(5),350–359 (2004).
  MedlineGoogle Scholar
• 65  Wu Y, Zhang X, Xiong Z et al. MicroPET imaging of glioma integrin {α}v{β}3 expression using (64)Cu-labeled tetrameric RGD peptide. J. Nucl. Med.46(10),1707–1718 (2005).
  Medline CASGoogle Scholar
• 66  Wadas TJ, Deng H, Sprague JE, Zheleznyak A, Weilbaecher KN, Anderson CJ. Targeting the αvβ3 integrin for small-animal PET/CT of osteolytic bone metastases. J. Nucl. Med.50(11),1873–1880 (2009).
  Medline CASGoogle Scholar
• 67  Gao L, Deng H, Zhao H et al. HTLV-1 tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood106(13),4294–4302 (2005).
  Medline CASGoogle Scholar
• 68  Siegrist W, Solca F, Stutz S et al. Characterization of receptors for α-melanocyte-stimulating hormone on human melanoma cells. Cancer Res.49(22),6352–6358 (1989).
  Medline CASGoogle Scholar
• 69  Tatro JB, Wen Z, Entwistle ML et al. Interaction of an α-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. Cancer Res.52(9),2545–2548 (1992).
  Medline CASGoogle Scholar
• 70  Jiang J, Sharma SD, Fink JL, Hadley ME, Hruby VJ. Melanotropic peptide receptors: membrane markers of human melanoma cells. Exp. Dermatol.5(6),325–333 (1996).
  Medline CASGoogle Scholar
• 71  Tatro JB, Atkins M, Mier JW et al. Melanotropin receptors demonstrated in situ in human melanoma. J. Clin. Invest.85(6),1825–1832 (1990).
  Medline CASGoogle Scholar
• 72  Wei L, Zhang X, Gallazzi F et al. Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A’’-Re(Arg-11)CCMSH. Nucl. Med. Biol.36(4),345–354 (2009).
  Medline CASGoogle Scholar
• 73  Ghanem GE, Comunale G, Libert A, Vercammen-Grandjean A, Lejeune FJ. Evidence for α-melanocyte-stimulating hormone (α-MSH) receptors on human malignant melanoma cells. Int. J. Cancer41(2),248–255 (1988).
  Medline CASGoogle Scholar
• 74  Cornish J, Callon KE, Mountjoy KG et al. α-melanocyte-stimulating hormone is a novel regulator of bone. Am. J. Physiol. Endocrinol. Metab.284(6),E1181–E1190 (2003).
  Medline CASGoogle Scholar
• 75  Sawyer TK, Castrucci AM, Staples DJ et al. Structure–activity relationships of [Nle4, D-Phe7]α-MSH. Discovery of a tripeptidyl agonist exhibiting sustained bioactivity. Ann. NY Acad. Sci.680,597–599 (1993).
  Medline CASGoogle Scholar
• 76  McQuade P, Miao Y, Yoo J, Quinn TP, Welch MJ, Lewis JS. Imaging of melanoma using ⁶⁴Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analog of α-MSH. J. Med. Chem.48(8),2985–2992 (2005).
  Medline CASGoogle Scholar
• 77  Wei L, Butcher C, Miao Y et al. Synthesis and biologic evaluation of ⁶⁴Cu-labeled rhenium-cyclized α-MSH peptide analog using a cross-bridged cyclam chelator. J. Nucl. Med.48(1),64–72 (2007).
  Medline CASGoogle Scholar
• 78  Nilsson FY, Tolmachev V. Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr. Opin. Drug Discov. Devel.10(2),167–175 (2007).
  Medline CASGoogle Scholar
• 79  Cheng Z, De Jesus OP, Kramer DJ et al.⁶⁴Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol. Imaging Biol.12(3),316–324 (2009).
  MedlineGoogle Scholar
• 80  Miao Z, Ren G, Liu H, Jiang L, Cheng Z. Small-animal PET imaging of human epidermal growth factor receptor-positive tumor with a ⁶⁴Cu labeled affibody protein. Bioconjug. Chem.21(5),947–954 (2010).
  Medline CASGoogle Scholar
• 81  Forster GJ, Engelbach MJ, Brockmann JJ et al. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor-positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide. Eur. J. Nucl. Med.28(12),1743–1750 (2001).
  Medline CASGoogle Scholar
• 82  Jamar F, Barone R, Mathieu I et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487) – a Phase I clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur. J. Nucl. Med. Mol. Imaging30(4),510–518 (2003).
  Medline CASGoogle Scholar
• 83  Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr. Pharm. Biotechnol.9(6),423–430 (2008).
  Medline CASGoogle Scholar
• 84  van Dongen GA, Vosjan MJ. Immuno-positron emission tomography: shedding light on clinical antibody therapy. Cancer Biother. Radiopharm.25(4),375–385 (2010).
  Medline CASGoogle Scholar
• 85  Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J.14(3),191–197 (2008).
  Medline CASGoogle Scholar
• 86  Williams LE, Wu AM, Yazaki PJ et al. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother. Radiopharm.16(1),25–35 (2001).
  Medline CASGoogle Scholar
• 87  McCabe KE, Wu AM. Positive progress in immunoPET – not just a coincidence. Cancer Biother. Radiopharm.25(3),253–261 (2010).
  Medline CASGoogle Scholar
• 88  Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov.2(1),52–62 (2003).
  Medline CASGoogle Scholar
• 89  Reardan DT, Meares CF, Goodwin DA et al. Antibodies against metal chelates. Nature316(6025),265–268 (1985).
  Medline CASGoogle Scholar
• 90  Goodwin DA, Meares CF, David GF et al. Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. Int. J. Rad. Appl. Instrum. B13(4),383–391 (1986).
  Medline CASGoogle Scholar
• 91  Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J. Nucl. Med.28(8),1294–1302 (1987).
  Medline CASGoogle Scholar
• 92  Sharkey RM, Karacay H, Cardillo TM et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin. Cancer Res.11(19),7109s–7121s (2005).
  Medline CASGoogle Scholar
• 93  Martensson L, Nilsson R, Ohlsson T, Sjogren HO, Strand SE, Tennvall J. Improved tumor targeting and decreased normal tissue accumulation through extracorporeal affinity adsorption in a two-step pretargeting strategy. Clin. Cancer Res.13(18),5572s–5576s (2007).
  Medline CASGoogle Scholar
• 94  Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using ⁶⁴Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur. J. Nucl. Med. Mol. Imaging34(6),850–858 (2007).
  Medline CASGoogle Scholar
• 95  Ping Li W, Meyer LA, Capretto DA, Sherman CD, Anderson CJ. Receptor-binding, biodistribution, and metabolism studies of Cu-64-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Cancer Biother. Radiopharm.23(2),158–171 (2008).
  MedlineGoogle Scholar
• 96  Niu G, Li Z, Xie J, Le QT, Chen X. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J. Nucl. Med.50(7),1116–1123 (2009).
  Medline CASGoogle Scholar
• 97  Elsasser-Beile U, Reischl G, Wiehr S et al. PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J. Nucl. Med.50(4),606–611 (2009).
  MedlineGoogle Scholar
• 98  Niu G, Li ZB, Cao QZ, Chen XY. Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with Cu-64-DOTA-trastuzumab. Eur. J. Nucl. Med. Mol. Imaging36(9),1510–1519 (2009).
  Medline CASGoogle Scholar
• 99  Wu AM, Yazaki PJ, Tsai S et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc. Natl Acad. Sci. USA97(15),8495–8500 (2000).
  Medline CASGoogle Scholar
• 100  Li L, Bading J, Yazaki PJ et al. A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies. Bioconjug. Chem.19(1),89–96 (2008).
  Medline CASGoogle Scholar
• 101  Philpott GW, Schwarz SW, Anderson CJ et al. RadioimmunoPET: detection of colorectal carcinoma with positron-emitting copper-64-labeled monoclonal antibody. J. Nucl. Med.36(10),1818–1824 (1995).
  Medline CASGoogle Scholar
• 102  Lovqvist A, Humm JL, Sheikh A et al. PET imaging of (86)Y-labeled anti-Lewis Y monoclonal antibodies in a nude mouse model: comparison between (86)Y and (111)In radiolabels. J. Nucl. Med.42(8),1281–1287 (2001).
  Medline CASGoogle Scholar
• 103  Nayak TK, Regino CA, Wong KJ et al. PET imaging of HER1-expressing xenografts in mice with ⁸⁶Y-CHX-A’’-DTPA-cetuximab. Eur. J. Nucl. Med. Mol. Imaging37(7),1368–1376 (2010).
  Medline CASGoogle Scholar
• 104  Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW. Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with ⁸⁶Y for quantitative PET of carcinoma. J. Nucl. Med.51(6),942–950 (2010).
  Medline CASGoogle Scholar
• 105  Schneider DW, Heitner T, Alicke B et al. In vivo biodistribution, PET imaging, and tumor accumulation of ⁸⁶Y- and ¹¹¹In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. J. Nucl. Med.50(3),435–443 (2009).
  Medline CASGoogle Scholar
• 106  Aerts HJ, Dubois L, Perk L et al. Disparity between in vivo EGFR expression and ⁸⁹Zr-labeled cetuximab uptake assessed with PET. J. Nucl. Med.50(1),123–131 (2009).
  Medline CASGoogle Scholar
• 107  Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. ⁸⁹Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.J. Nucl. Med.51(8),1293–1300 (2010).
  Medline CASGoogle Scholar
• 108  Nagengast WB, de Vries EG, Hospers GA et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med.48(8),1313–1319 (2007).
  Medline CASGoogle Scholar
• 109  Borjesson PK, Jauw YW, Boellaard R et al. Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin. Cancer Res.12(7 Pt. 1),2133–2140 (2006).▪ First clinical study of zirconium-89.
  MedlineGoogle Scholar
• 110  Borjesson PK, Jauw YW, de Bree R et al. Radiation dosimetry of ⁸⁹Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J. Nucl. Med.50(11),1828–1836 (2009).
  MedlineGoogle Scholar
• 111  Dijkers EC, Oude Munnink TH, Kosterink JG et al. Biodistribution of ⁸⁹Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin. Pharmacol. Ther.87(5),586–592 (2010).
  Medline CASGoogle Scholar
• 112  Glaus C, Rossin R, Welch MJ, Bao G. In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug. Chem.21(4),715–722 (2010).
  Medline CASGoogle Scholar
• 113  Minchin RF, Martin DJ. Nanoparticles for molecular imaging – an overview. Endocrinology151(2),474–481 (2010).
  Medline CASGoogle Scholar
• 114  Chen K, Li ZB, Wang H, Cai W, Chen X. Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur. J. Nucl. Med. Mol. Imaging35(12),2235–2244 (2008).
  Medline CASGoogle Scholar
• 115  Michalet X, Pinaud FF, Bentolila LA et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science307(5709),538–544 (2005).
  Medline CASGoogle Scholar
• 116  Bruchez M Jr., Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science281(5385),2013–2016 (1998).
  Medline CASGoogle Scholar
• 117  Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science281(5385),2016–2018 (1998).
  Medline CASGoogle Scholar
• 118  Cai W, Chen K, Li ZB, Gambhir SS, Chen X. Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J. Nucl. Med.48(11),1862–1870 (2007).
  Medline CASGoogle Scholar
• 119  Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labeling and sensing. Nat. Mater.4(6),435–446 (2005).
  Medline CASGoogle Scholar
• 120  Vuu K, Xie J, McDonald MA et al. Gadolinium-rhodamine nanoparticles for cell labeling and tracking via magnetic resonance and optical imaging. Bioconjug. Chem.16(4),995–999 (2005).
  Medline CASGoogle Scholar
• 121  van Tilborg GA, Mulder WJ, Deckers N et al. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug. Chem.17(3),741–749 (2006).
  Medline CASGoogle Scholar
• 122  Rieter WJ, Kim JS, Taylor KM, An H, Lin W, Tarrant T. Hybrid silica nanoparticles for multimodal imaging. Angew. Chem. Int. Ed. Engl.46(20),3680–3682 (2007).
  Medline CASGoogle Scholar
• 123  Kim JS, Rieter WJ, Taylor KM, An H, Lin W. Self-assembled hybrid nanoparticles for cancer-specific multimodal imaging. J. Am. Chem. Soc.129(29),8962–8963 (2007).
  Medline CASGoogle Scholar
• 124  Islam T, Josephson L. Current state and future applications of active targeting in malignancies using superparamagnetic iron oxide nanoparticles. Cancer Biomark.5(2),99–107 (2009).
  Medline CASGoogle Scholar
• 125  Josephson L, Kircher MF, Mahmood U, Tang Y, Weissleder R. Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug. Chem.13(3),554–560 (2002).
  Medline CASGoogle Scholar
• 126  Jennings LE, Long NJ. ‘Two is better than one’ – probes for dual-modality molecular imaging. Chem. Commun. (Camb.) (24), 3511–3524 (2009).
  MedlineGoogle Scholar
• 127  Nahrendorf M, Zhang H, Hembrador S et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation117(3),379–387 (2008).
  Medline CASGoogle Scholar
• 128  Holland JP, Caldas-Lopes E, Divilov V et al. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. PLoS One5(1),e8859 (2010).
  MedlineGoogle Scholar
• 129  Dijkers EC, Kosterink JG, Rademaker AP et al. Development and characterization of clinical-grade ⁸⁹Zr-trastuzumab for HER2/neu immunoPET imaging. J. Nucl. Med.50(6),974–981 (2009).
  Medline CASGoogle Scholar